Search Results 921-930 of 19765 for Hepatitis+C

  1. First-in-Human Study of FLX925 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia - Mayo Clinic

    Patients known to be positive for hepatitis B or to have active hepatitis C infection; Any evidence of ongoing graft-versus-host disease (GVHD) in subjects ...

  2. Study To Check The Safety Of Fazirsiran And Learn If Fazirsiran Can Help People With Liver Disease And Scarring (Fibrosis) Due To An Abnormal Version Of Alpha-1 Antitrypsin Protein - Mayo Clinic

    hepatitis B or C, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson disease, alcoholic hepatitis, hemochromatosis, liver cancer, history ...

  3. Segesterone acetate and ethinyl estradiol (vaginal route) - Side effects & dosage - Mayo Clinic

    Do not use this medicine together with medicine to treat hepatitis C virus infection, including ombitasvir/paritaprevir/ritonavir, with or without dasabuvir ( ...

  4. Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma - Mayo Clinic

    ... hepatitis B virus, or hepatitis C; Autologous stem cell transplant less than 3 months prior to enrollment; Patients who have undergone allogeneic stem cell or ...

  5. A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia - Mayo Clinic

    Hepatitis B or C infection, Alcoholic Liver Disease (ALD), Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (PBC), or Primary Sclerosing

  6. Nausea and vomiting - Mayo Clinic

    Hepatitis C: How common is sexual transmission? Hepatitis C: What happens in end-stage liver disease? ... How do COVID-19 antibody tests differ from diagnostic ...

  7. Autoimmune hepatitis - Doctors and departments - Mayo Clinic

    This type of hepatitis happens when the immune system attacks the liver with destructive antibodies. Immune-suppressing medicine is the main treatment.

  8. A Study of Grapiprant and Pembrolizumab in Patients with Advanced or Progressive MSS Colorectal Cancer - Mayo Clinic

    Has a known history of Hepatitis B or known active Hepatitis C virus infection. Clinically significant (i.e., active) cardiovascular disease: cerebral ...

  9. Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure - Mayo Clinic

    Known intrinsic liver disease (e.g., cirrhosis, hepatitis A, chronic hepatitis B or hepatitis C virus infection). If serology is positive and PCR is known ...

  10. Immunotherapy Clinical Trials - Mayo Clinic Research

    The purpose of this study is to determine whether INO-8000 alone or in combination with INO-9012 (IL-12) is safe and induces a Hepatitis C virus-specific immune ...